Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 6/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068725 | 1.00 | METAP2 (0.39) | METAP2SMPD3PRKDCPDE10APIM1 | |
| SCHEMBL2068014 | 1.00 | METAP2 (0.39) | METAP2SMPD3PRKDCPDE10APIM1 | |
| SCHEMBL2068134 | 0.89 | PIM1 (0.33) | SMPD3PDE10APIM1PIM3PIM2 | |
| SCHEMBL2068582 | 0.79 | MAP4K4 (0.43) | PDE10A | |
| SCHEMBL2790964 | 0.77 | IKBKB (0.40) | SMPD3PRKDCPDE10A | |
| SCHEMBL2794080 | 0.77 | IKBKB (0.40) | SMPD3PRKDCPDE10A | |
| SCHEMBL2068403 | 0.76 | KDM4E (0.40) | SMPD3PDE10AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2067363 | 0.76 | HTR3E (0.37) | SMPD3PDE10AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21345365 | 0.76 | HTR3E (0.54) | PRKDCPDE10APIM1PIM3PIM2 | |
| SCHEMBL21345364 | 0.76 | HTR3E (0.54) | PRKDCPDE10APIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | METAP2 4283/4885SMPD3 1264/4885PRKDC 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.